LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Severity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: A nationwide retrospective cohort study.

    Van't Oever, Renske M / Zwiers, Carolien / de Haas, Masja / le Cessie, Saskia / Lopriore, Enrico / Oepkes, Dick / Verweij, E J T Joanne

    BJOG : an international journal of obstetrics and gynaecology

    2023  Volume 131, Issue 6, Page(s) 769–776

    Abstract: Objective: Pregnant women who received at least one intrauterine transfusion (IUT) for haemolytic disease of the fetus and newborn (HDFN) in the preceding pregnancy are presumed to have a high likelihood of requiring IUTs again, often starting at an ... ...

    Abstract Objective: Pregnant women who received at least one intrauterine transfusion (IUT) for haemolytic disease of the fetus and newborn (HDFN) in the preceding pregnancy are presumed to have a high likelihood of requiring IUTs again, often starting at an earlier gestational age. Our aim was to quantify these risks in a large national cohort.
    Design: Retrospective cohort study of a nationwide Dutch database.
    Setting: The Netherlands.
    Population: All women treated in The Netherlands with IUTs for Rhesus D (RhD)- or Kell-mediated HDFN between 1999 and 2017 and their follow-up pregnancies were included. Pregnancies with an antigen-negative fetus were excluded.
    Methods: Electronic patient files were searched for the number and gestational age of each IUT, and analysed using descriptive statistics and linear regression.
    Main outcome measures: Percentage of women requiring one or more IUTs again in the subsequent pregnancy, and gestational age at first IUT in both pregnancies.
    Results: Of the 321 women in our study population, 21% (69) had a subsequent ongoing pregnancy at risk. IUTs were administered in 86% (59/69) of cases. In subsequent pregnancies, the median gestational age at first IUT was 3 weeks earlier (interquartile range -6.8 to 0.4) than in the preceding pregnancy.
    Conclusions: Our study shows that pregnant women with a history of IUTs in the previous pregnancy are highly likely to require IUTs again, and on average 3 weeks earlier. Clinicians need to be aware of these risks and ensure timely referral, and close surveillance from early pregnancy onwards. Additionally, for women with a history of IUT and their caregivers, this information is essential to enable adequate preconception counselling.
    MeSH term(s) Infant, Newborn ; Humans ; Female ; Pregnancy ; Blood Transfusion, Intrauterine ; Retrospective Studies ; Erythroblastosis, Fetal/epidemiology ; Erythroblastosis, Fetal/therapy ; Fetus ; Gravidity
    Language English
    Publishing date 2023-09-24
    Publishing country England
    Document type Journal Article
    ZDB-ID 2000931-8
    ISSN 1471-0528 ; 0306-5456 ; 1470-0328
    ISSN (online) 1471-0528
    ISSN 0306-5456 ; 1470-0328
    DOI 10.1111/1471-0528.17674
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Monoclonal RhD prophylaxis: high time to evaluate efficacy.

    Verweij, Ejt / Tura, Abera Kenay / Gure, Tadesse / Pyuza, Jeremia / Mchome, Bariki / Kawaza, Kondwani / Moons, Peter / de Winter, Derek / Van't Oever, Renske / Spitalnik, Steven / van der Schoot, C Ellen / van den Akker, Thomas

    Lancet (London, England)

    2024  Volume 403, Issue 10429, Page(s) 806–807

    Language English
    Publishing date 2024-02-18
    Publishing country England
    Document type Letter
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(23)01888-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Identification and management of fetal anemia due to hemolytic disease.

    van 't Oever, Renske M / Zwiers, Carolien / de Winter, Derek / de Haas, Masja / Oepkes, Dick / Lopriore, Enrico / Verweij, E J Joanne

    Expert review of hematology

    2022  Volume 15, Issue 11, Page(s) 987–998

    Abstract: Introduction: Hemolytic disease of the fetus and newborn (HDFN) is a condition caused by maternal alloantibodies against fetal red blood cells (RBCs) that can cause severe morbidity and mortality in the fetus and newborn. Adequate screening programs ... ...

    Abstract Introduction: Hemolytic disease of the fetus and newborn (HDFN) is a condition caused by maternal alloantibodies against fetal red blood cells (RBCs) that can cause severe morbidity and mortality in the fetus and newborn. Adequate screening programs allow for timely prevention and intervention resulting in significant reduction of the disease over the last decades. Nevertheless, HDFN still occurs and with current treatment having reached an optimum, focus shifts toward noninvasive therapy options.
    Areas covered: This review focusses on the timely identification of high risk cases and antenatal management. Furthermore, we elaborate on future perspectives including improvement of screening, identification of high risk cases and promising treatment options.
    Expert opinion: In high-income countries mortality and morbidity rates due to HDFN have drastically been reduced over the last decades, yet worldwide anti-D mediated HDFN still accounts for 160,000 perinatal deaths and 100,000 patients with disabilities every year. Much of these deaths and disabilities could have been avoided with proper identification and prophylaxis. By implementing sustainable prevention, screening, and disease treatment measures in all countries this will systemically reduce unnecessary perinatal deaths. There is a common responsibility to engage in this cause.
    MeSH term(s) Infant, Newborn ; Humans ; Female ; Pregnancy ; Perinatal Death ; Erythroblastosis, Fetal/diagnosis ; Erythroblastosis, Fetal/etiology ; Erythroblastosis, Fetal/prevention & control ; Hemolysis ; Fetal Diseases/diagnosis ; Fetal Diseases/etiology ; Fetal Diseases/therapy ; Isoantibodies ; Anemia
    Chemical Substances Isoantibodies
    Language English
    Publishing date 2022-10-31
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2516804-6
    ISSN 1747-4094 ; 1747-4086
    ISSN (online) 1747-4094
    ISSN 1747-4086
    DOI 10.1080/17474086.2022.2138853
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: History and current standard of postnatal management in hemolytic disease of the fetus and newborn.

    De Winter, Derek P / Hulzebos, Christian / Van 't Oever, Renske M / De Haas, Masja / Verweij, Ejt Joanne / Lopriore, Enrico

    European journal of pediatrics

    2022  Volume 182, Issue 2, Page(s) 489–500

    Abstract: Since the discovery of the Rh blood group system in 1940, a greater understanding of hemolytic disease of the fetus and newborn (HDFN) was gained. In the years thereafter, researchers and clinicians came to the current understanding that fetal and ... ...

    Abstract Since the discovery of the Rh blood group system in 1940, a greater understanding of hemolytic disease of the fetus and newborn (HDFN) was gained. In the years thereafter, researchers and clinicians came to the current understanding that fetal and neonatal red blood cells (RBC) are hemolyzed by maternal alloantibodies directed against RBC antigens potentially leading to severe disease. Preventative measures, such as Rhesus(D) immunoprophylaxis (RhIG), have greatly decreased the prevalence of Rh(D)-mediated HDFN, although a gap between high-income countries and middle- to low-income countries was created largely due to a lack in availability and high costs of RhIG. Other important developments in the past decades have improved the identification, monitoring, and care of pregnancies, fetuses, and neonates with HDFN. Prenatally, fetal anemia may occur and intrauterine transfusions may be needed. Postnatally, pediatricians should be aware of the (antenatally determined) risk of hemolysis in RBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for anemia in the late phase of the disease. Through this review, we aim to provide an overview of important historic events and to provide hands-on guidelines for the delivery and postnatal management of neonates with HDFN. Secondarily, we aim to describe recent scientific findings and evidence gaps.
    Conclusion:  Multiple developments have improved the identification, monitoring, and care of pregnancies and neonates with HDFN throughout the centuries. Pediatricians should be aware of the (antenatally determined) risk of hemolysis in RBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for late anemia in the late phase of the disease. Future studies should be set in an international setting and ultimately aim to eradicate HDFN on a global scale.
    What is known: • Developments have led to a greater understanding of the pathophysiology, an improved serological identification and monitoring of at-risk cases and the current pre- and postnatal treatment.
    What is new: • This review provides the pediatrician with hands-on guidelines for the delivery and postnatal management of neonates with HDFN. • Future studies should be set in an international setting with the ultimate aim of eradicating HDFN.
    MeSH term(s) Pregnancy ; Female ; Humans ; Hemolysis ; Erythroblastosis, Fetal/diagnosis ; Erythroblastosis, Fetal/therapy ; Hematologic Diseases ; Anemia ; Fetus ; Hyperbilirubinemia
    Language English
    Publishing date 2022-12-05
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 194196-3
    ISSN 1432-1076 ; 0340-6199 ; 0943-9676
    ISSN (online) 1432-1076
    ISSN 0340-6199 ; 0943-9676
    DOI 10.1007/s00431-022-04724-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Are fetal bilirubin levels associated with the need for neonatal exchange transfusions in hemolytic disease of the fetus and newborn?

    Ree, Isabelle M C / van 't Oever, Renske M / Zwiers, Carolien / Verweij, E J T / Oepkes, Dick / de Haas, Masja / Lopriore, Enrico

    American journal of obstetrics & gynecology MFM

    2021  Volume 3, Issue 3, Page(s) 100332

    Abstract: Background: Fetal bilirubin is routinely measured at our center when taking a pretransfusion blood sample at intrauterine transfusions in hemolytic disease of the fetus and newborn. However, the clinical value of fetal bilirubin assessment is not well ... ...

    Abstract Background: Fetal bilirubin is routinely measured at our center when taking a pretransfusion blood sample at intrauterine transfusions in hemolytic disease of the fetus and newborn. However, the clinical value of fetal bilirubin assessment is not well known, and the information is rarely used. We speculated that there could be a role for this measurement in predicting the need for neonatal exchange transfusion.
    Objective: This study aimed to evaluate the predictive value of fetal bilirubin for exchange transfusions in severe hemolytic disease of the fetus and newborn.
    Study design: A total of 186 infants with Rh alloantibody-mediated hemolytic disease of the fetus and newborn treated with one or more intrauterine transfusions at the Leiden University Medical Center between January 2006 and June 2020 were included in this observational study. Antenatal and postnatal factors were compared between infants with and without exchange transfusion treatments. The primary outcome was the fetal bilirubin levels before the last intrauterine transfusion in relation to the need for exchange transfusion.
    Results: In a multivariate logistic regression analysis, the fetal bilirubin level before the last intrauterine transfusions (odds ratio, 1.32; 95% confidence interval, 1.09-1.61 per 1 mg/dL) and the total number of intrauterine transfusions (odds ratio, 0.63; 95% confidence interval, 0.44-0.91 per intrauterine transfusion) were independently associated with the need for exchange transfusion. The area under the curve was determined at 0.71. A Youden index was calculated at 0.43. The corresponding fetal bilirubin level was 5 mg/dL and had a sensitivity of 79% and a specificity of 64%.
    Conclusion: A high fetal bilirubin level before the last intrauterine transfusion was associated with a high likelihood of neonatal exchange transfusion.
    MeSH term(s) Bilirubin ; Blood Transfusion, Intrauterine ; Erythroblastosis, Fetal/diagnosis ; Exchange Transfusion, Whole Blood ; Female ; Fetus ; Humans ; Infant ; Infant, Newborn ; Pregnancy
    Chemical Substances Bilirubin (RFM9X3LJ49)
    Language English
    Publishing date 2021-02-18
    Publishing country United States
    Document type Journal Article ; Observational Study
    ISSN 2589-9333
    ISSN (online) 2589-9333
    DOI 10.1016/j.ajogmf.2021.100332
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top